Iron Sequestration and Anemia of Inflammation

被引:294
作者
Ganz, Tomas [1 ,2 ]
Nemeth, Elizabeta [1 ]
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol, Los Angeles, CA 90095 USA
关键词
TUMOR-NECROSIS-FACTOR; RECEPTOR ANTIBODY; INTRAVENOUS IRON; HEPCIDIN EXPRESSION; NEISSERIA-MENINGITIDIS; HEMODIALYSIS-PATIENTS; CASTLEMANS-DISEASE; DEFICIENCY ANEMIA; PEPTIDE HEPCIDIN; FERRIC GLUCONATE;
D O I
10.1053/j.seminhematol.2009.06.001
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Anemia of chronic disease, also called anemia of inflammation, is characterized by hypoferremia due to iron sequestration that eventually results in iron-restricted erythropoiesis. During the last decade, the molecular mechanisms of iron sequestration have been found to center on cytokine-stimulated overproduction of the iron-regulatory hormone hepcidin. The inflammatory cytokine interleukin-6 (IL-6) is a particularly prominent inducer of hepcidin, but other cytokines are likely to contribute as well. Hepcidin excess causes the endocytosis and proteolysis of the sole known cellular iron exporter, ferroportin, trapping iron in macrophages and iron-absorbing enterocytes. The supply of iron to hemoglobin synthesis becomes limiting, eventually resulting in anemia. Depending on the details of the underlying disease, other inflammation-related mechanisms may also contribute to anemia. Semin Hematol 46:387-393. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:387 / 393
页数:7
相关论文
共 79 条
[31]
HOLBEIN BE, 1980, INFECT IMMUN, V29, P886
[33]
A mouse model of juvenile hemochromatosis [J].
Huang, FW ;
Pinkus, JL ;
Pinkus, GS ;
Fleming, MD ;
Andrews, NC .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (08) :2187-2191
[34]
HUANG FW, 2005, ASH ANN M ABSTR, V106, P511
[35]
ANAEMIA OF RHEUMATOID ARTHRITIS AND IRON THERAPY [J].
HUME, R ;
CURRIE, WJC ;
TENNANT, M .
ANNALS OF THE RHEUMATIC DISEASES, 1965, 24 (05) :451-&
[36]
Ferric gluconate reduces epoetion requirements in hemodialysis patients with elevated ferritin [J].
Kapoian, Toros ;
O'Mara, Neeta B. ;
Singh, Ajay K. ;
Moran, John ;
Rizkala, Adel R. ;
Geronemus, Robert ;
Kopelman, Robert C. ;
Dahl, Naomi V. ;
Coyne, Daniel W. .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2008, 19 (02) :372-379
[37]
Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman's disease like symptoms emerged in IL-6 transgenic mice [J].
Katsume, A ;
Saito, H ;
Yamada, Y ;
Yorozu, K ;
Ueda, O ;
Akamatsu, K ;
Nishimoto, N ;
Kishimoto, T ;
Yoshizaki, K ;
Ohsugi, Y .
CYTOKINE, 2002, 20 (06) :304-311
[38]
Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease [J].
Kawabata, Hiroshi ;
Tomosugi, Naohisa ;
Kanda, Junya ;
Tanaka, Yasuhiro ;
Yoshizaki, Kazuyuki ;
Uchiyama, Takashi .
HAEMATOLOGICA, 2007, 92 (06) :857-858
[39]
Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS [J].
Kemna, E ;
Pickkers, P ;
Nemeth, E ;
van der Hoeven, H ;
Swinkels, D .
BLOOD, 2005, 106 (05) :1864-1866
[40]
Expression of Rgmc, the murine ortholog of hemojuvelin gene, is modulated by development and inflammation, but not by iron status or erythropoietin [J].
Krijt, J ;
Vokurka, M ;
Chang, KT ;
Necas, E .
BLOOD, 2004, 104 (13) :4308-4310